Signal Transducer and Activator of Transcription 6
STAT6 is the primary transcription factor driving Type 2 (Th2) inflammatory responses. Activated downstream of IL-4 and IL-13, it controls IgE production, eosinophil recruitment, mucus hypersecretion, and skin barrier dysfunction. It is the master regulator of the biological pathway that dupilumab partially blocks. An oral degrader of STAT6 could replicate biologic-class efficacy in pill form.
IL-4 and IL-13 bind their shared receptor complex (IL-4Rα/IL-13Rα1), triggering JAK1 and TYK2 phosphorylation of STAT6 at Tyr641. Phosphorylated STAT6 dimerizes and translocates to the nucleus, where it binds GAS elements to drive transcription of Th2 effector genes: CCL11 (eotaxin), CCL17/22, IgE class-switch genes (IL-4 dependent), MUC5AC (mucin), and TSLP. Dupilumab blocks this pathway upstream at the receptor level. Degrading STAT6 protein eliminates signaling regardless of which cytokines are present.
Traditional small molecule STAT6 inhibitors have failed because STAT6 is a transcription factor with no classical deep hydrophobic pocket. SH2 domain inhibitors showed poor selectivity across STAT family members. PROTAC degradation bypasses the need for a high-affinity binding pocket — sub-stoichiometric engagement is sufficient to trigger ubiquitination and proteasomal degradation. Kymera's KT-621 achieved picomolar-level STAT6 degradation in blood and skin, exceeding the depth of pathway suppression seen with dupilumab in mechanistic biomarker studies.
STAT6 SH2 domain inhibitors (small molecules) — failed due to poor selectivity and potency. No approved small molecule STAT6 inhibitor exists. Upstream pathway blocked by dupilumab (anti-IL-4Rα biologic), tralokinumab (anti-IL-13), and lebrikizumab (anti-IL-13).
pChEMBL = −log₁₀(IC₅₀). Higher value = more potent. Dashed line = 100 nM threshold. Showing top binding compounds in ChEMBL (224 total activities).
First-in-class oral STAT6 degrader. Wholly-owned. Phase 1b in atopic dermatitis demonstrated: deep, dose-dependent STAT6 protein reduction in blood and skin biopsies; picomolar degradation potency; clinically meaningful EASI-50 responses; improvements in comorbid asthma and allergic rhinitis without biologics.
Phase 1b data (2025): >80% STAT6 degradation in PBMCs at optimal dose; meaningful EASI-50 responses; favorable safety profile. First human validation of STAT6 degradation as a therapeutic mechanism.
No other company has a targeted protein degrader program against STAT6 in the clinic. Kymera holds first-mover advantage in this target.
Primary endpoint in most AD Phase 2/3 trials. Responders show ≥75% reduction in EASI score.
Clear or almost clear skin. Co-primary endpoint with EASI-75 in AD trials including BROADEN2.
Patient-reported quality of life. Secondary endpoint across AD, CRSwNP, PN indications.
Composite severity measure including extent, intensity, and subjective symptoms.
Primary endpoint for asthma trials including BREADTH (KT-621 asthma Phase 2b).
Lung function endpoint for asthma trials. Change from baseline is a key secondary endpoint.
Total patient potential: 140M+ globally with Type 2 inflammatory diseases across all indications